Cerebrolysin peptide is a molecule that can be administered intravenously and is used for treating neurological conditions like stroke, TBI (traumatic brain injury), and Alzheimer’s disease. It is a combination of several neurotrophic factors and peptide fragments that are similar to our natural internal nerve growth factors that maintain peripheral and central nervous system cellular efficiency. It has been shown to improve outcomes after stroke and TBI, including recovery of communication abilities in infants with cerebral palsy in 6 randomized double blind clinical trials (DB-RCT’s).
It can also help improve the symptoms of Parkinson’s Disease by decreasing alpha-synuclein levels in patients. Additionally, cerebrolysin is able to stimulate the release of new neurons in the brain and boost blood flow to the area. This is all achieved by lowering the breakdown of the blood-brain barrier.
This unique peptide has been found to be very effective in human clinical trials for stroke, traumatic brain injuries, and even Alzheimer’s Disease. It can increase the rate of recovery in stroke victims by reducing oxidative stress and improving blood flow to the affected areas, and it also improves motor function. It has also been shown to help prevent the onset of Alzheimer’s by inhibiting a key protein involved in amyloid deposition, and by stimulating new synapse formation.
In addition, cerebrolysin has been shown to improve the effects of chronic migraine headaches by lowering pro-inflammatory cytokines in the bloodstream. As a result, it has the potential to change the lives of many people who suffer from this debilitating condition.